文献速递心脏核医学肿瘤 PET/CT

[18F]FDG PET显像鉴别心脏肿块:诊断性能与参数变异性双Meta分析的系统综述更新

[18F]FDG PET imaging in the differentiation of cardiac masses: an updated systematic review and dual Meta-Analysis of diagnostic performance and parameter variability.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-29

该系统综述与Meta分析纳入15项研究共1114例患者,评估[18F]FDG PET/CT鉴别心脏肿块良恶性的诊断性能。汇总敏感度为89.2%(95%CI:85-92%),特异度为82.8%(95%CI:78-87%);恶性病变SUVmax范围5.6-14.3,显著高于良性病变的1.1-5.3(p<0.001)。

要点

  • [18F]FDG PET/CT鉴别恶性心脏肿块汇总敏感度89.2%、特异度82.8%。
  • 恶性病变SUVmax范围5.6-14.3,良性病变1.1-5.3,差异有统计学意义(p<0.001)。
  • 在超声心动图、心脏磁共振或CT结论不明确时,PET/CT有助于活检引导和治疗规划。

核心结论

  • [18F]FDG PET/CT在鉴别心脏肿块良恶性方面具有稳健的诊断准确性,SUVmax是有价值的恶性标志物。
  • 将其整合入多模态影像策略可提高诊断确定性并优化患者管理。
  • 原文指出需要标准化显像方案和进一步多中心前瞻性研究来完善其临床应用并验证其预后潜力。

研究设计与样本

  • 系统综述与Meta分析,纳入评估[18F]FDG PET/CT对心脏肿块诊断准确性的研究。
  • 共纳入15项研究、1114例患者。
  • 采用随机效应模型汇总敏感度和特异度,并二次分析恶性与良性病变间SUVmax的差异。

主要发现

  • [18F]FDG PET/CT检测恶性心脏肿块的汇总敏感度为89.2%(95%CI:85-92%),汇总特异度为82.8%(95%CI:78-87%)。
  • 恶性病变SUVmax范围为5.6-14.3,良性肿块范围为1.1-5.3,恶性病变显著高于良性(p<0.001)。
  • 在超声心动图、心脏磁共振或CT结论不明确时,PET/CT尤其有效,有助于活检引导和治疗规划。

关键数值与推荐

  • 恶性心脏肿块诊断汇总敏感度89.2%(95%CI:85-92%)、特异度82.8%(95%CI:78-87%)。
  • 恶性病变SUVmax范围5.6-14.3 vs 良性病变范围1.1-5.3(p<0.001)。

临床怎么用

  • 原文结论认为[18F]FDG PET/CT在鉴别心脏肿块良恶性方面具有稳健诊断准确性,SUVmax为有价值的恶性标志物。
  • 原文指出将其整合入多模态影像策略可提高诊断确定性并优化患者管理。
  • 原文指出需要标准化显像方案和进一步多中心前瞻性研究以完善临床应用并验证预后潜力。

局限性

  • 原文指出需要标准化显像方案。
  • 原文指出需要进一步多中心前瞻性研究来完善其临床应用并验证其预后潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cardiac masses (CMs) encompass a heterogeneous group of benign, malignant, and pseudotumoural lesions, posing diagnostic challenges due to their rarity and varied aetiologies. Given the limitations of conventional imaging modalities in differentiating benign from malignant masses, [18F]FDG PET/CT has emerged as a promising technique by providing metabolic information. This systematic review and meta-analysis aimed to evaluate the diagnostic performance of [18F]FDG PET/CT in characterising CMs and assess semi-quantitative parameters' role in distinguishing malignant from benign lesions. METHODS: A systematic review and meta-analysis were conducted, including studies evaluating the diagnostic accuracy of [18F]FDG PET/CT in CMs. Sensitivity and specificity were pooled using a random-effects model, and a secondary analysis examined differences in SUVmax between malignant and benign lesions. RESULTS: Fifteen studies enrolling 1114 patients met inclusion criteria. The pooled sensitivity and specificity of [18F]FDG PET/CT in detecting malignant CMs were 89.2% (95% CI: 85-92%) and 82.8% (95% CI: 78-87%), respectively. Malignant lesions exhibited significantly higher SUVmax values (range: 5.6-14.3) than benign masses (range: 1.1-5.3, p < 0.001). PET/CT proved particularly effective in cases with inconclusive findings from echocardiography, cardiac magnetic resonance, or CT, contributing to biopsy guidance and treatment planning. CONCLUSIONS: [18F]FDG PET/CT demonstrates robust diagnostic accuracy in differentiating benign from malignant cardiac masses, with SUVmax as a valuable malignancy marker. Its integration into multimodal imaging strategies enhances diagnostic certainty and optimises patient management. Despite these advantages, standardised imaging protocols and further multicentre prospective studies are warranted to refine its clinical application and validate its prognostic potential.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rizzo A, Viccaro V, Pavon AG, et al. [18F]FDG PET imaging in the differentiation of cardiac masses: an updated systematic review and dual Meta-Analysis of diagnostic performance and parameter variability. Eur J Nucl Med Mol Imaging. 2025. PMID: 40298987. doi:10.1007/s00259-025-07289-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。